Germline gain-of-function mutations of ALK disrupt central nervous system development
- PMID: 21972109
- DOI: 10.1002/humu.21442
Germline gain-of-function mutations of ALK disrupt central nervous system development
Abstract
Neuroblastoma (NB) is a frequent embryonal tumor of sympathetic ganglia and adrenals with extremely variable outcome. Recently, somatic amplification and gain-of-function mutations of the anaplastic lymphoma receptor tyrosine kinase (ALK) gene, either somatic or germline, were identified in a significant proportion of NB cases. Here we report a novel syndromic presentation associating congenital NB with severe encephalopathy and abnormal shape of the brainstem on brain MRI in two unrelated sporadic cases harboring de novo, germline, heterozygous ALK gene mutations. Both mutations are gain-of-function mutations that have been reported in NB and NB cell lines. These observations further illustrate the role of oncogenes in both tumour predisposition and normal development, and shed light on the pleiotropic and activity-dependent role of ALK in humans. More generally, missing germline mutations relative to the spectrum of somatic mutations reported for a given oncogene may be a reflection of severe effects during embryonic development, and may prompt mutation screening in patients with extreme phenotypes.
© 2011 Wiley-Liss, Inc.
Comment in
-
New germline syndrome with brainstem abnormalities and neuroblastoma, caused by ALK mutation.Hum Mutat. 2011 Mar;32(3):v. doi: 10.1002/humu.21487. Hum Mutat. 2011. PMID: 21972113 No abstract available.
Similar articles
-
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.Nature. 2008 Oct 16;455(7215):967-70. doi: 10.1038/nature07398. Nature. 2008. PMID: 18923523
-
Clinical feature of anaplastic lymphoma kinase-mutated neuroblastoma.J Pediatr Surg. 2012 Oct;47(10):1789-96. doi: 10.1016/j.jpedsurg.2012.05.007. J Pediatr Surg. 2012. PMID: 23084186
-
Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.Cancer Lett. 2012 Apr 1;317(1):72-7. doi: 10.1016/j.canlet.2011.11.013. Epub 2011 Nov 13. Cancer Lett. 2012. PMID: 22085494
-
Molecular pathogenesis of peripheral neuroblastic tumors.Oncogene. 2010 Mar 18;29(11):1566-79. doi: 10.1038/onc.2009.518. Epub 2010 Jan 25. Oncogene. 2010. PMID: 20101209 Review.
-
Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma.Cancer Lett. 2005 Oct 18;228(1-2):51-8. doi: 10.1016/j.canlet.2005.01.055. Cancer Lett. 2005. PMID: 15949893 Review.
Cited by
-
Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma.Cold Spring Harb Mol Case Stud. 2021 Aug 2;7(4):a006064. doi: 10.1101/mcs.a006064. Print 2021 Aug. Cold Spring Harb Mol Case Stud. 2021. PMID: 34210658 Free PMC article.
-
Research progress of neuroblastoma related gene variations.Oncotarget. 2017 Mar 14;8(11):18444-18455. doi: 10.18632/oncotarget.14408. Oncotarget. 2017. PMID: 28055978 Free PMC article. Review.
-
Developmental genes significantly afflicted by aberrant promoter methylation and somatic mutation predict overall survival of late-stage colorectal cancer.Sci Rep. 2015 Dec 22;5:18616. doi: 10.1038/srep18616. Sci Rep. 2015. PMID: 26691761 Free PMC article.
-
Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides.Cancers (Basel). 2019 Feb 26;11(3):275. doi: 10.3390/cancers11030275. Cancers (Basel). 2019. PMID: 30813562 Free PMC article. Review.
-
Improving the rigor of mutation reports: biologic parentage and de novo mutations.Hum Mutat. 2012 Nov;33(11):1501-2. doi: 10.1002/humu.22131. Epub 2012 Jul 2. Hum Mutat. 2012. PMID: 22715147 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
